Impact of long-term probucol administration of blood lipoprotein cholesterol levels and glutathione activity in patients with coronary atherosclerosis and hyperlipidemia

The authors present results of 6-month probucoli (lipomal) therapy in patients with coronary heart disease concurrent with Types 2a and 2b hyperlipidemia. There were 22 and 23 % increases in total cholesterol and low density lipoprotein cholesterol, respectively, whereas the levels of high density lipoprotein decreased and triglycerides remained unchanged. Having antioxidative properties, probucol enhanced the activity of the antioxidative anzyme glutathione peroxidase on an average twice, which should be borne in mind in evaluating the efficiency of treatment